Evidence map›Paper›PMID 42295078›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2026

Shikonin suppresses diffuse large B-cell lymphoma progression by inducing ferritinophagy and ferroptosis

Can Chen, Xiaofei Chen, Xilian Huang, Yaping Xie, Pengfei Shi, Shenxian Qian, Zhenzhen Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Can ChenDepartment of Hematology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China.
Xiaofei ChenZhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Xilian HuangDepartment of Hematology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China.
Yaping XieDepartment of Hematology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China.
Pengfei ShiDepartment of Hematology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China.
Shenxian QianDepartment of Hematology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China.
Zhenzhen ChenDepartment of Hematology, Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University, Hangzhou, Zhejiang, China.ORCID 0000-0002-8938-1449

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Shikonin, a natural compound, exhibits antitumor effects in DLBCL, but its mechanism remains unclear. Shikonin's cytotoxicity in DLBCL cells was assessed by MTT assays. Ferroptosis and lipid peroxidation markers were analysed

Indexed as

Antineoplastic AgentsDown-RegulationFerroptosisLymphoma, Large B-Cell, DiffuseNaphthoquinonesRNA, Long NoncodingAnimalsCell ProliferationCell SurvivalDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMiceMice, NudeMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsNaphthoquinonesRNA, Long NoncodingshikoninADPGK-AS1Diffuse large B-cell lymphomaferritinophagyferroptosisshikonin

Identifiers

PMID42295078
PMCPMC13270872

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.